RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.
about
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancerThe design and discovery of water soluble 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule targeting antitumor agentsEfficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidenceThe efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis.Evaluation of Left Ventricular Ejection Fractions in Breast Cancer Patients Undergoing Long-Term Trastuzumab Treatment.Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer.Trastuzumab cardiotoxicity: from clinical trials to experimental studies.Dermatologic Adverse Events Associated With Use of Adjuvant Lapatinib in Combination With Paclitaxel and Trastuzumab for HER2-Positive Breast Cancer: A Case Series Analysis.Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine.Practical consensus recommendations regarding the management of HER2 neu positive early breast cancer.
P2860
Q26785612-1DAB7260-9EDD-49E2-BF7D-4AE3002EE1B4Q33872751-8DCC48C6-E77E-402E-97E4-6A79D565BBDCQ36250585-4038EE08-A754-449C-97C6-BF6A8BC1F76CQ36967905-D8FABD17-44BE-4E8A-8C1D-4520265FB835Q37543832-62B0F3D8-394C-447E-8D74-68DD5E06C8D9Q38238613-37DD60CE-DDEC-48AA-979B-2298298D7E1AQ38974785-BE107668-D7D0-4A68-A7A8-39E29E53A840Q41018872-BE262A04-CA2C-4095-9514-5E8556707653Q41603225-067A2A93-EFD6-4EDF-AFCF-7E594D3DDC92Q55080728-A873D9B7-D97F-42A3-B00F-6CC50227753B
P2860
RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
RC0639: phase II study of pacl ...... e HER2-positive breast cancer.
@ast
RC0639: phase II study of pacl ...... e HER2-positive breast cancer.
@en
type
label
RC0639: phase II study of pacl ...... e HER2-positive breast cancer.
@ast
RC0639: phase II study of pacl ...... e HER2-positive breast cancer.
@en
prefLabel
RC0639: phase II study of pacl ...... e HER2-positive breast cancer.
@ast
RC0639: phase II study of pacl ...... e HER2-positive breast cancer.
@en
P2093
P2860
P1476
RC0639: phase II study of pacl ...... ge HER2-positive breast cancer
@en
P2093
Alvaro Moreno-Aspitia
Ann E McCullough
David Johnson
Donald Northfelt
Edith A Perez
Frances M Palmieri
Gerardo Colon-Otero
Ismael Ghanem-Cañete
Kathleen S Tenner
Richard Rodeheffer
P2860
P2888
P304
P356
10.1007/S10549-013-2469-2
P407
P50
P577
2013-03-12T00:00:00Z